How much does Lurbinectedin cost?

Lurbinectedin is a drug used to treat certain types of cancer, particularly recurrent small cell lung cancer (SCLC) and recurrent synovial sarcoma (Myxoid/round cell liposarcoma). Rubicatin is approved to treat recurrent small cell lung cancer, a highly aggressive and often difficult-to-treat type of lung cancer. Additionally, it is used to treat recurrent synovial sarcoma, a rare soft tissue tumor.

Rubicatin has not yet been launched in China, so it is not included in medical insurance. Patients cannot purchase it domestically and need to purchase Rubicatin through overseas channels. There is only the original drug Rubicatin in foreign countries, and the price is relatively expensive. In comparison, the original drug in Singapore is slightly cheaper, priced at more than 30,000, and there are other American versions of the original drug, priced at more than 90,000.

Rubicatine belongs to a class of drugs called"DNAtopoisomeraseIIαinhibitors". It interferes with the activity of DNAtopoisomeraseIIα and prevents the repair and replication of DNA, thus leading to the death of tumor cells. Clinical trial results of rubicatin show that it can significantly extend progression-free survival (Progression-Free Survival, PFS) in some patients with recurrent small cell lung cancer and synovial sarcoma. This means that after patients receive rubicatin treatment, the growth of tumors is effectively controlled and the disease will not progress for a relatively longer period of time.

The use of Rubicatin may be associated with some side effects, including fatigue, nausea, vomiting, loss of appetite, and low platelet count. These side effects need to be closely monitored and managed during treatment. The use of Rubicatin needs to be determined based on the patient's specific situation and the recommendations of the doctor. Treatment options typically take into account the patient's health, tumor characteristics, and other factors.